Aptose to Participate in Upcoming Investor Conferences

SAN DIEGO and TORONTO, March 02, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO) (TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:

The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing first-in-class agents directed against fundamental drug targets at the leading edge of cancer research. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences
Greg Chow, CFO
647-479-9825
[email protected]

SMP Communications
Susan Pietropaolo
201-923-2049
[email protected]

You May Also Be Interested In

• ScanSource to Acquire MicroAge, a Leading IT Solutions Integrator
• Mattamy Homes Announces Leadership Transition for U.S. Business
• Sedifly Appoints Callian Capital Group Managing Partner Ameer Ibrahim as a Board Advisor